Efficacy of Raltegravir monotherapy and in combination with Etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor.

Trial Profile

Efficacy of Raltegravir monotherapy and in combination with Etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Etravirine (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 01 Aug 2017 Results assessing efficacy of raltegravir as monotherapy and in combination with etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor, were published in the JAIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top